The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It also reviews various agents, both commercially available and investigational, that are used to treat malignant diseases.
The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the US Department of the Army or Department of Defense.
Get full access to this article
View all access options for this article.
References
1.
EdsmyrF., BerlinT., BomanJ., DuchekM.Intravesical therapy with adriamycin in patients with superficial bladder tumors. Eur Urol.1980; 6(3): 132–136.
2.
JakseG., HofstadterF., MarbergerH.Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ of the bladder. J Urol.1981; 125(2): 185–190.
3.
KimS.K., AnH.J., ChoJ.H.Intravesical instillation therapy with adriamycin for bladder cancer in the Korean study group. Cancer Chemother Pharmacol.1983; 11(suppl):S22–S24.
4.
GlashanR.W.Treatment of carcinoma in situ of the bladder with doxorubicin (adriamycin). Cancer Chemother Pharmacol.1983; 11(suppl):S35–S37.
5.
KhannaO.P., SonD.L., MazerH.Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: multicenter study interim report. Urology.1987; 30(6): 520–528.
6.
KhannaO.P., SonD.L., MazerH.Superficial bladder cancer treated with intravesical bacillus Calmette-Guérin or adriamycin: follow-up report. Urology.1988; 31(4): 287–293.
7.
KhannaO.P., SonD.L., MazerH.Multicenter study of superficial bladder cancer treated with intravesical bacillus Calmette-Guérin or adriamycin. Urology.1990; 35(2): 101–108.
8.
JauhiainenK., RintalaE.Superficial urinary bladder cancer. Results from the Finnbladder studies and a review on instillation treatments. Ann Chir Gynaecol Suppl.1993; 206: 31–38.
9.
AkazaH., KoisoK., KotakeT.Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol.1992; 30(suppl):S15–S20.
10.
ShinoharaN., NonomuraK., TanakaM.Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder Cancer Collaborative Group. Cancer Chemother Pharmacol.1994; 35(suppl):S41–S45.
11.
EtoH., OkaY., UenoK.Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group. Cancer Chemother Pharmacol.1994; 35(suppl): S46–S51.
12.
HuangJ.S., ChenW.H., LinC.C.A randomized trial comparing intravesical instillations of mitoxantrone and doxorubicin in patients with superficial bladder cancer. Chang Gung Med J.2003; 26(2): 91–97.
13.
ShuinT., KubotaY., NoguchiS.A phase II study of prophylactic intravesical chemotherapy with 4′-epirubicin in recurrent superficial bladder cancer: comparison of 4′-epirubicin and adriamycin. Cancer Chemother Pharmacol.1994; 35(suppl):S52–S56.
14.
AkazaH., KoisoK., KotakeT.Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol.1992; 30(suppl):S15–S20.
15.
AkazaH., IsakaS., KoisoK.Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group. Cancer Chemother Pharmacol.1987; 20(suppl):S91–S96.
16.
HiraoY., OkajimaE., OharaS.Prophylactic treatment for superficial bladder cancer following transurethral resection. Cancer Chemother Pharmacol.1987; 20(suppl):S85–S90.
17.
IsakaS., OkanoT., ShimazakiJ.Prophylaxis of superficial bladder cancer with instillation of adriamycin or mitomycin C. Cancer Chemother Pharmacol.1987; 20(suppl):S77–S80.
18.
NiijimaT., KoisoK., AkazaH.Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol.1983; 11(suppl):S79–S82.
19.
SchwaiboldH., PichlmeierU., KlingenbergerH.J., HulandH.Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?Eur Urol.1997; 31(2): 153–159.
20.
Ali-el-DeinB., el-BazM., AlyA.N., ShamaaS., AshamallahAl. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol.1997; 158(1): 68–73.
21.
BouffiouxC., KurthK.H., BonoA.Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol.1995; 153(3 Pt 2):934–941.
22.
BouffiouxC., DenisL., OosterlinckW.Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group. J Urol.1992; 148(2 Pt 1):297–301.
23.
Martinez-PineiroJ.A., Jimenez LeonJ., Martinez-PineiroL.Jr.. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol.1990; 143(3): 502–506.
24.
Martinez-PineiroJ.A., Jimenez LeonJ., Martinez-PineiroL.Jr.. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study. Prog Clin Biol Res.1989; 310: 237–252.
25.
HulandH., KloppelG., FeddersenI.Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Urol.1990; 144(1): 68–71.
26.
TsushimaT., MatsumuraY., OzakiY., YoshimotoJ., OhmoriH.Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer. Cancer Chemother Pharmacol.1987; 20(suppl):S72–S76.
27.
ObamaT., MatsumuraY., OhmoriH.Intravesical chemotherapy. Cancer Chemother Pharmacol.1987; 20(suppl): S60–S62.
28.
SchulmanC.C., DenisL.J., OosterlinckW.Early adjuvant adriamycin in superficial bladder carcinoma. Cancer Chemother Pharmacol.1983; 11(suppl): S32–S34.
29.
Blinst Italian Cooperative Group.Intravesical doxorubicin for the prophylaxis of superficial bladder tumors. A multicenter study. Cancer.1984; 54(4): 756–761.
30.
GarnickM.B., SchadeD., IsraelM., MaxwellB., RichieJ.P.Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma. J Urol.1984; 131(1): 43–46.
31.
KubotaY., NoguchiS., ShuinT.Preoperative doxorubicin instillation in recurrent superficial bladder cancer. Cancer Chemother Pharmacol.1987; 20(suppl): S56–S59.
32.
MatsumuraY., AkazaH., IsakaS.The 4th study of prophylactic intravesical chemotherapy with adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol.1992; 30(suppl): S10–S14.
33.
ZinckeH., UtzD.C., TaylorW.F., MyersR.P., LearyF.J.Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol.1983; 129(3): 505–509.
34.
HerrH.W.Intravesical therapy. A critical review. Urol Clin North Am.1987; 14(2): 399–404.
35.
SmithJ.A.Jr., LabaskyR.F., CockettA.T., FracchiaJ.A., MontieJ.E., RowlandR.G.Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS). J Urol.1999; 162(5): 1697–1701.
